Lenalidomide is a thalidomide analogue that is used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). It has been approved for the treatment of MM in the United States, Canada, Europe, Australia, New Zealand and Japan. Lenalidomide was approved by the FDA in 2006 for use in combination with dexamethasone as a second-line therapy for patients with MM who have received at least one prior therapy. In 2007 it was approved as monotherapy for patients with newly diagnosed MM who are not candidates for stem cell transplantation or who have relapsed after stem cell transplantation.
-Lenalidomide is a drug that is used to treat multiple myeloma, a type of cancer that starts in the bone marrow and affects the production of blood cells.
-The drug has been shown to be effective in treating patients with multiple myeloma who have received at least one prior therapy.
-Lenalidomide is also being studied for use as a treatment for other types of cancer, including breast cancer and non-Hodgkin lymphoma.
-In 2013, lenalidomide was approved by the FDA as an oral treatment for people with relapsed or refractory mantle cell lymphoma (MCL).
Industry Growth Insights published a new data on “Lenalidomide Market”. The research report is titled “Lenalidomide Market research by Types (5 mg Capsules, 10 mg Capsules, 15 mg Capsules, 25 mg Capsules), By Applications (Multiple myeloma (MM), Myelodysplastic syndromes (MDS)), By Players/Companies Celgene, Exova”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lenalidomide Market Research Report
By Type
5 mg Capsules, 10 mg Capsules, 15 mg Capsules, 25 mg Capsules
By Application
Multiple myeloma (MM), Myelodysplastic syndromes (MDS)
By Companies
Celgene, Exova
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Lenalidomide Market Report Segments:
The global Lenalidomide market is segmented on the basis of:
Types
5 mg Capsules, 10 mg Capsules, 15 mg Capsules, 25 mg Capsules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multiple myeloma (MM), Myelodysplastic syndromes (MDS)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Exova
Highlights of The Lenalidomide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5 mg Capsules
- 10 mg Capsules
- 15 mg Capsules
- 25 mg Capsules
- By Application:
- Multiple myeloma (MM)
- Myelodysplastic syndromes (MDS)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lenalidomide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lenalidomide is a chemotherapy drug used to treat multiple myeloma. It works by stopping the growth of cancer cells.
Some of the major companies in the lenalidomide market are Celgene, Exova.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lenalidomide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lenalidomide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lenalidomide Market - Supply Chain
4.5. Global Lenalidomide Market Forecast
4.5.1. Lenalidomide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lenalidomide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lenalidomide Market Absolute $ Opportunity
5. Global Lenalidomide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lenalidomide Market Size and Volume Forecast by Type
5.3.1. 5 mg Capsules
5.3.2. 10 mg Capsules
5.3.3. 15 mg Capsules
5.3.4. 25 mg Capsules
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lenalidomide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lenalidomide Market Size and Volume Forecast by Application
6.3.1. Multiple myeloma (MM)
6.3.2. Myelodysplastic syndromes (MDS)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lenalidomide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lenalidomide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lenalidomide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lenalidomide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lenalidomide Demand Share Forecast, 2019-2026
9. North America Lenalidomide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lenalidomide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lenalidomide Market Size and Volume Forecast by Application
9.4.1. Multiple myeloma (MM)
9.4.2. Myelodysplastic syndromes (MDS)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lenalidomide Market Size and Volume Forecast by Type
9.7.1. 5 mg Capsules
9.7.2. 10 mg Capsules
9.7.3. 15 mg Capsules
9.7.4. 25 mg Capsules
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lenalidomide Demand Share Forecast, 2019-2026
10. Latin America Lenalidomide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lenalidomide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lenalidomide Market Size and Volume Forecast by Application
10.4.1. Multiple myeloma (MM)
10.4.2. Myelodysplastic syndromes (MDS)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lenalidomide Market Size and Volume Forecast by Type
10.7.1. 5 mg Capsules
10.7.2. 10 mg Capsules
10.7.3. 15 mg Capsules
10.7.4. 25 mg Capsules
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lenalidomide Demand Share Forecast, 2019-2026
11. Europe Lenalidomide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lenalidomide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lenalidomide Market Size and Volume Forecast by Application
11.4.1. Multiple myeloma (MM)
11.4.2. Myelodysplastic syndromes (MDS)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lenalidomide Market Size and Volume Forecast by Type
11.7.1. 5 mg Capsules
11.7.2. 10 mg Capsules
11.7.3. 15 mg Capsules
11.7.4. 25 mg Capsules
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lenalidomide Demand Share, 2019-2026
12. Asia Pacific Lenalidomide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lenalidomide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lenalidomide Market Size and Volume Forecast by Application
12.4.1. Multiple myeloma (MM)
12.4.2. Myelodysplastic syndromes (MDS)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lenalidomide Market Size and Volume Forecast by Type
12.7.1. 5 mg Capsules
12.7.2. 10 mg Capsules
12.7.3. 15 mg Capsules
12.7.4. 25 mg Capsules
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lenalidomide Demand Share, 2019-2026
13. Middle East & Africa Lenalidomide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lenalidomide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lenalidomide Market Size and Volume Forecast by Application
13.4.1. Multiple myeloma (MM)
13.4.2. Myelodysplastic syndromes (MDS)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lenalidomide Market Size and Volume Forecast by Type
13.7.1. 5 mg Capsules
13.7.2. 10 mg Capsules
13.7.3. 15 mg Capsules
13.7.4. 25 mg Capsules
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lenalidomide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Lenalidomide Market: Market Share Analysis
14.2. Lenalidomide Distributors and Customers
14.3. Lenalidomide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celgene
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Exova
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
